37 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
for various reasons, including noncompliance with regulatory requirements or safety concerns, among others;
lower than anticipated retention rates … recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement business strategy, which could harm our business
F-3
EX-4.1
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
strategic and/or financial objectives, as well as retention elements.
Le conseil d’administration, le comité de rémunération ou tout autre organe
F-3
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
circumstances, the board of directors may be paid variable compensation, depending on the achievement of certain performance criteria or for retention
F-3
EX-4.1
q73giusxt02u86n1kf
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.3
2pa 6g2io
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K/A
EX-99.2
7d20h dld7kyk
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.2
j8b4r
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-1.1
otyr 638g37bm7
5 Mar 21
Current report (foreign)
8:15am
424B5
nuac9eg
5 Mar 21
Prospectus supplement for primary offering
7:55am
6-K
EX-1.1
41yvscdodjbycpq
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
vq96kf0e egsy
8 Sep 20
Prospectus supplement for primary offering
7:31am
F-3
20i6uizfkkr4u5ylw
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
EX-4.1
09iz 6rj0mnv
7 Aug 19
Shelf registration (foreign)
8:24am
424B5
u9rrme 3j2d9ho96o4v0
7 Aug 19
Prospectus supplement for primary offering
8:18am